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Abstract
Background: Haemodialysis is the most common form of renal replacement therapy in Nigeria. The high cost of
haemodialysis has made optimal therapy of end-stage renal disease difficult in Nigeria. This paper is a review of
data collected over two years of provision of dialysis services in a new tertiary hospital in Southern Nigeria.
Methods: This retrospective analysis is done on data obtained from the patient case files and dialysis records in
the first two years of provision of dialysis services in our centre. A gender comparison of the patients’ baseline
sociodemographic, clinical and biochemical was performed and a logistic regression model used to assess the
predictors of mortality.
Results: A total of 98 patients had 471 sessions in the two years under review. Males and females had similar
characteristics at baseline except for a higher median serum urea in the males. The commonest causes of end-
stage renal disease were chronic glomerulonephritis (34.5%), hypertension (32.1%) and diabetes mellitus (17.9%).
The main predictor of mortality was under treatment with haemodialysis due to inability to pay for more than a
few dialysis sessions.
Conclusions: This study has highlighted the unchanging demographics of our advanced kidney failure patients.
Efforts should be aimed at subsidizing the cost of dialysis for our teeming population of dialysis dependent chronic
kidney disease patients.
Background
Haemodialysis is a form of treatment where accumu-
lated solute and fluid are removed from a patient who
has total or near-total loss of kidney function using hae-
modialysis machines which utilize extracorporeal blood
lines and artificial kidney called ‘dialyzer’[1]. It is indi-
cated for the treatment of Acute Kidney Injury, acute
exacerbation of Chronic Renal Failure and End-Stage
Renal Disease (ESRD) [1,2]
Haemodialysis is the most commonly used modality of
Renal Replacement Therapy (RRT) worldwide.3 A global
survey of RRT options showed that 24% of all haemo-
dialysis patients are treated in the United States and
19% in the European Union [3]. In Sub-Saharan Africa
including Nigeria, haemodialysis is the most common
modality of RRT [4-6]. The other options (peritoneal
dialysis and renal transplantation) are largely uncommon
due to the extremely exorbitant cost, lack of facilities
and manpower, and the predominantly urban location
of the renal care centres [4,6,7]. The distribution of dia-
lysis centres in Nigeria with concentration of the centres
in the south western part of the country and the Federal
Capital territory is as shown in Figure 1.
However, despite the recent increase in the number of
haemodialysis centres, the recommendation in the devel-
oped world on the optimal dose of haemodialysis is
often not achieved for most of the ESRD patients in
Nigeria. This is mainly due to the high cost of haemo-
dialysis ($160 per session in Nigeria) and ancillary treat-
ment modalities and interruptions of dialysis services
due to frequent breakdown of machines and erratic
power supply. For these reasons, it is particularly diffi-
cult for patients to maintain regular therapy [4,5].
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The National Health Insurance Scheme in Nigeria
does not cover the cost of haemodialysis and other renal
replacement therapies. As a result, most patients pay
out of their pocket. This is an enormous burden for
these patients in a country where the Gross Domestic
Product (GDP) Per Capita is USD 1,450 and 70% of the
population lives below the poverty line [8].
The multiple barriers to accessing RRT underscore the
need to identify prevention strategies and methods for
fair and equitable access to RRT.
We reviewed our experience over a 2-year period at
the Haemodialysis Unit of the University of Uyo Teach-




This is a retrospective analysis of data at the Dialysis Unit
of the University of Uyo Teaching Hospital in southern
Nigeria. Set up in January 2008, it is the only dialysis unit
in the former south eastern state (comprising Akwa Ibom
and Cross River states) with an estimated population of six
million and receives referrals from both states and its envir-
ons. The unit has three functional dialysis machines. How-
ever, there are no machines dedicated to dialyzing patients
who have HIV, Hepatitis B and Hepatitis C virus infection.
Vascular access for most patients was via femoral catheters.
Jugular catheters were not used because this would have
added an extra USD 110 to the cost of care. The patients
gave informed consent before being commenced on ther-
apy and understood that treatment depended on their abil-
ity to pay for this service. Ethical approval for this study
was obtained from the University of Uyo Teaching Hospital
Human Research Ethics Committee.
Data extraction/analysis
Data was extracted from patients’ medical files and dia-
lysis charts for the period from January 2008 to
Figure 1 Map of Nigeria showing the distribution of dialysis centres.
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December 2009. Sociodemographic data, clinical charac-
teristics including blood pressure, clinical diagnosis, age
at initiation of dialysis, biochemical and haematocrit
levels, dialysis access routes and regularity at dialysis
were also extracted. As each patient with ESRD requires
at least three dialysis sessions of 12 to 15 hours per
week, we defined regularity in our centre as having at
least 70% of scheduled dialysis sessions per week (i.e. 2
sessions per week).
Descriptive analysis of the characteristics of the
patients was performed using Chi-square for categorical
variables and the Wilcoxon rank sum test for continu-
ous variables that were not normally distributed. A
logistic regression model was built to determine factors
that predicted mortality in our patients. All analysis was
done using STATA 10, StataCorp, Texas USA.
Results
A total of 98 patients were dialyzed in the period under
review. They had a total of 471 dialysis sessions with the
median number of sessions per patient being three. Fifty
seven percent of the patients were males while 43%
were females with a male: female ratio of 1.3:1. The
median age at initiation of dialysis was 47.5 years (Males
47 years; Females 48 years) with a range of 12-72 years.
Most were in the 20-59 year age group (Figure 2).
Eight four (85.7%) of the patients had chronic kidney
disease (CKD) while the remainder had acute kidney
injury (AKI). Of those with CKD, 29(34.5%) had chronic
glomerulonephritis, 27(32.1%) had hypertensive nephro-
sclerosis while 15(17.9%) had Diabetic nephropathy. The
remainder had adult polycystic kidney disease, obstruc-
tive uropathy and sickle cell nephropathy.
The aetiology of acute kidney injury in this cohort
included Pre-eclampsia/eclampsia 4(28.6%), drug
nephrotoxicity 4(28.6%), sepsis 3 (21.4%), acute glomer-
ulonephritis 2(14.3%), hypovolemic shock from ruptured
ectopic pregnancy 1 (7.1%). Two (14.3%) of the AKI
patients died: one from disseminated intravascular coa-
gulopathy (DIC) complicating sepsis and the other from
progression of uraemia due to lack of funds to pay for
more sessions of dialysis.
The clinical and biochemical parameters compared by
gender are as summarized in table 1. The mean haema-
tocrit level was 23% (19-29) for males and 22% (20-26)
for females. There was a significant difference in the
serum urea levels between males and females (27.6
μmol/l versus 22.6 μmol/l, P-value 0.007). Other para-
meters including serum creatinine and blood pressures
were similar. Vascular access for dialysis for 92.6% of
patients was via the femoral veins. Only 7 (7.4%)
patients had permanent dialysis access (all arteriovenous












Figure 2 Age distribution of dialysis patients by gender.
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fistulae). The mean kidney size for individuals presumed
to have chronic glomerulonephritis was 8.78 × 3.73 cm
for the right kidney and 8.66 × 3.97 cm for the left
kidneys.
Only 11 (13.1%) of our patients had achieved at least
70% of their scheduled dialysis sessions. Seventeen
patients received only one session of dialysis, 20 received
two sessions; 28 received three sessions; 8 received four
sessions; 11 received 5-10 sessions; 4 received 11-15 ses-
sions while only 6 patients received more than 15 ses-
sions in the period of follow up. The highest number of
sessions achieved by a patient was 73 sessions in this
period. At the end of the second year of providing this
service, just about 27% of the patients were still alive.
Most of the patients died at home because they could
no longer afford haemodialysis.
A multivariate logistic regression model built for the
end-stage renal disease patients showed that patients
who were able to achieve at least 70% of their scheduled
dialysis sessions, had their risk of mortality within the
first 2 years of initiating haemodialysis reduced by 93%
(Table 2).
Discussion
The very high mortality seen in this study is a combina-
tion of several factors namely, late presentation, co mor-
bid conditions and inability to pay for the recommended
adequate dialysis owing to high cost. Cost of dialysis
averages $160 per session in most centres in Nigeria
with an estimated GDP of 5.6% for 2009 [9] and lack of
health insurance for a majority of people. Indeed, stu-
dies in other parts of the country show a similar situa-
tion [5,7,10]. The main predictor of mortality in this
study was low dialysis frequency due to the inability to
pay for more than a small number of dialysis sessions.
This has been demonstrated in similar studies in coun-
tries with similar health indices [11,12]. An analysis of
survival on dialysis in a facility in Ghana shows that
duration on dialysis and number of dialysis sessions
were very strong predictors of survival among their
cohort of patients [13]. Similarly, dialysis frequency and
weekly duration of haemodialysis less than 8 hours per
week were independent risk factors for mortality in a
cohort in Lithuania [14]. Even in resource rich settings,
data from the Dialysis Outcomes and Practice Patterns
Study (DOPPS) has shown that non adherence among
dialysis patients including skipping as little as a dialysis
session per month predicts mortality [15]. In our study,
even when we considered adequate dialysis as meeting
70% of scheduled sessions which in many cases is still
sub optimal, there was a reduction in mortality in those
who had at least 70% of their scheduled dialysis sessions.
This suggests that more dialysis would have been bene-
ficial. Unfortunately, not many of our patients were able
to afford dialysis regularly and for a long time resulting
in the high mortality rates seen. Some patients have to
Table 1 Gender Comparison of Clinical Parameters
CLINICAL/BIOCHEMICAL CHARACTERISTIC MALE FEMALE P-VALUE
Serum creatinine (μmol/L) 1318 ± 646 1353 ± 747 0.82
Serum urea (mmol/L), IQR 27.6 (22.2-35.8) 22.6 (18.9-26.8) 0.007
Haematocrit (%) 23 (19-29) 22 (20-26) 0.40
Systolic blood pressure (mmHg) 156 ± 24 161 ± 33 0.46
Diastolic blood pressure (mmHg) 94.5 ± 17.4 98.2 ± 22.2 0.38
Table 2 Logistic Regression Model for Predictors of Mortality
VARIABLE UNIVARIATE ANALYSIS
ODDS RATIO (95%CI, P-VALUE)
MULTIVARIATE ANALYSIS
ODDS RATIO (95%CI, P-VALUE)
Age (5 years) 1.08 (0.9-1.29, 0.42) 1.09 (0.73-1.61, 0.69)
Serum Creatinine (5 μmol/L) 0.99 (0.99-1.01, 0.67) 0.99 (0.99-1.01, 0.80)
Serum Urea (mmol/L) 1.02 (0.97-1.07, 0.48) 1.05 (0.93-1.19, 0.42)
Packed Cell Volume (%) 1.01 (0.95-1.12, 0.92) 0.85 (0.72-1.01, 0.07)
Systolic blood pressure (mmHg) 1.00 (0.98-1.02, 0.67) 0.99 (0.94-1.03, 0.57)
Diastolic blood pressure (mmHg) 1.00 (0.98-1.03, 0.84) 0.97 (0.92-1.03, 0.28)
Not regular 1 1
Regular 0.24 (0.08-0.67, 0.01) 0.07 (0.01-0.56, 0.01)
Chronic glomerulonephritis 1 1
Diabetic nephropathy 1.86 (0.45-7.73, 0.40) 1.29 (0.04-44.58, 0.89)
Hypertensive nephrosclerosis 1.33 (0.47-3.77, 0.59) 1.40 (0.10-19.52, 0.80)
The model was 92% sensitive and 63.6% specific and the Hosmer-Lemeshow test suggested a good fit for the model. The area under the receiver operator
characteristic (ROC) curve for the model was 0.87.
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commute long distances to access this service. This
trend will obviously continue unless there is remarkable
expansion of renal care services to many more places, a
liberalization of the import regime for dialysis software
and consumables to force down the cost of dialysis and
the expansion of Health Insurance coverage to include
renal replacement therapy especially haemodialysis.
It bears repeating therefore that the high cost of dialy-
sis has militated against access to adequate dialysis. The
ethical aspects of initiating dialysis in those with ESRD
who presumably may be unable to afford more than a
few sessions needs to be further studied in our environ-
ment. Often, patients, their relatives or sponsors are
provided information on the prognosis and the huge
long term cost of RRT before initiating dialysis. In spite
of this, they still opt for the initial treatment. Not mind-
ing the obvious fact that they may not be able to sustain
the therapy in the long term.
The baseline demographic characteristics of our inci-
dent patients on dialysis in terms of the age and sex are
similar with earlier reports in Nigeria and elsewhere
[5,7,10]. It is worrisome that in a developing country
such as ours, the economically productive age group is
the most affected.
The aetiology of chronic kidney disease still reflects
present trends in Nigeria and sub Saharan Africa where
chronic glomerulonephritis (CGN) is the commonest
cause of CKD [5,10]. Data from Europe and Australia
are similar although diabetes rather than hypertension is
the second common cause of ESRD. This may reflect
lifestyle differences, nutritional variability and a greater
control of infectious diseases. The diagnoses of CGN
were presumptive based on the relatively young age of
the patient, severely impaired serum creatinine levels
and markedly shrunken kidney sizes on ultrasound scan.
Predialysis anemia was common in our patients unar-
guably because of late presentation and poor anaemia
management practices before referral for dialysis. His-
torically, our patients present late preferring to resort to
herbal remedies and over the counter medications. Even
then, studies from Europe and Asia also show a high
prevalence of predialysis anaemia (68% and 75% respec-
tively) in spite of availability of better and affordable
renal care services [16-18]. Although anaemia is both a
risk factor for CKD as well as a factor that accelerates
progression of CKD leading to a worsening of the cardi-
ovascular state, it did not predict mortality in our
cohort.
Limitations
The limitations of this study were firstly, its retrospec-
tive design. In establishments such as ours where elec-
tronic records are lacking, record keeping can be quite
poor. Expectedly, the quantity and quality of data
extracted may be suboptimal. Secondly additional base-
line information like parathyroid hormone levels, serum
calcium and phosphate levels were lacking. These were
not routinely done because of the additional cost. This
lack precluded our exploration of other risk factors for
mortality in our cohort.
Conclusion
This study has highlighted the unchanging demo-
graphics of our advanced kidney failure patients. Fre-
quency of dialysis even as defined in our environment is
a strong predictor of mortality. Efforts should be aimed
at subsidizing the cost of dialysis for our teeming popu-
lation of dialysis dependent chronic kidney disease
patients who would otherwise not be able to afford reg-
ular dialysis.
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